| Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD (NCT05438732) | VisionCare, Inc. | 2022-06-16 |
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT05019521) | Alexion Pharmaceuticals, Inc. | 2021-08-23 |
| Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) (NCT04358471) | Hemera Biosciences | 2021-07-31 |
| ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration (NCT04744662) | ONL Therapeutics | 2021-07-08 |
| Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study (NCT05963646) | Institute of Molecular and Clinical Ophthalmology Basel | 2021-03-16 |
| A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy (NCT04656561) | Annexon, Inc. | 2021-02-26 |
| Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression (NCT04739319) | Center for Eye Research Australia | 2021-02-02 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT04615325) | Hoffmann-La Roche | 2020-12-08 |
| Oral Postbiotics in Patients With Macular Atrophy (NCT05391074) | Institut de la Macula y la Retina | 2020-12-01 |
| Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD (NCT04676854) | Science Corporation | 2020-11-24 |
| A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT04607148) | Genentech, Inc. | 2020-11-16 |
| Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration (NCT04339764) | National Eye Institute (NEI) | 2020-09-23 |
| A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration (NCT04643886) | Gemini Therapeutics, Inc. | 2020-07-30 |
| A Study of NGM621 in Participants With Geographic Atrophy (NCT04465955) | NGM Biopharmaceuticals, Inc | 2020-07-22 |
| A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) (NCT04435366) | IVERIC bio, Inc. | 2020-06-22 |
| First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration (NCT04246866) | Gemini Therapeutics, Inc. | 2019-12-19 |
| Study of NGM621 in Participants With Geographic Atrophy (NCT04014777) | NGM Biopharmaceuticals, Inc | 2019-07-26 |
| A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (NCT03972709) | Genentech, Inc. | 2019-06-03 |
| GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (NCT03815825) | Ionis Pharmaceuticals, Inc. | 2019-03-04 |
| GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) (NCT03894020) | Gyroscope Therapeutics Limited | 2019-01-08 |
| FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD (NCT03846193) | Gyroscope Therapeutics Limited | 2018-12-17 |
| Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy (NCT03777332) | Apellis Pharmaceuticals, Inc. | 2018-11-05 |
| Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (NCT03525600) | Apellis Pharmaceuticals, Inc. | 2018-08-31 |
| A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (NCT03525613) | Apellis Pharmaceuticals, Inc. | 2018-08-31 |
| Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (NCT02895815) | Janssen Pharmaceutical K.K. | 2018-04-09 |
| Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (NCT03446144) | Ionis Pharmaceuticals, Inc. | 2018-03-16 |
| Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (NCT03295877) | Genentech, Inc. | 2017-09-21 |
| Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) (NCT02745119) | Hoffmann-La Roche | 2016-07-21 |
| Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD (NCT02800356) | Ospedale San Raffaele | 2016-06-01 |
| Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD (NCT02590692) | Regenerative Patch Technologies, LLC | 2016-02-16 |
| Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (NCT02686658) | IVERIC bio, Inc. | 2015-12-15 |
| A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (NCT02659098) | Janssen Research & Development, LLC | 2015-12-04 |
| Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy (NCT02503332) | Apellis Pharmaceuticals, Inc. | 2015-09-24 |
| A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT02479386) | Hoffmann-La Roche | 2015-06-24 |
| A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy (NCT02288559) | Genentech, Inc. | 2015-03-30 |
| A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT02399072) | Hoffmann-La Roche | 2015-03-30 |
| Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort (NCT07424235) | IRCCS Ospedale San Raffaele | 2015-01-01 |
| A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT02247531) | Hoffmann-La Roche | 2014-10-06 |
| Sparing of the Fovea in Geographic Atrophy Progression (NCT02332343) | University Hospital, Bonn | 2014-10-01 |
| A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT02247479) | Hoffmann-La Roche | 2014-09-18 |
| A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT02087085) | Allergan | 2014-05-09 |
| Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration (NCT02137915) | StemCells, Inc. | 2014-04-01 |
| Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration (NCT02130531) | Kubota Vision Inc. | 2014-04-01 |
| High Resolution Retinal Imaging (NCT01866371) | University of Pennsylvania | 2013-05-01 |
| Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) (NCT01782989) | Paul Yates, MD, PhD | 2013-02-01 |
| Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO (NCT01692938) | Optos, PLC | 2012-10-01 |
| Micropulse Laser for Geographic Atrophy (NCT01799564) | Institut de la Macula y la Retina | 2012-08-01 |
| A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD) (NCT01603043) | Alcon Research | 2012-06-01 |
| An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy (NCT01602120) | Genentech, Inc. | 2012-05-29 |
| Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy (NCT01675947) | National Eye Institute (NEI) | 2012-02-01 |
| Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) (NCT01527500) | Novartis Pharmaceuticals | 2012-01-25 |
| Sirolimus for Advanced Age-Related Macular Degeneration (NCT01445548) | National Eye Institute (NEI) | 2011-09-01 |
| A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy (NCT01093170) | Mark Kleinman | 2011-03-01 |
| A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy (NCT01229215) | Genentech, Inc. | 2011-02-01 |
| Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE) (NCT01272076) | Carl Zeiss Meditec, Inc. | 2011-01-01 |
| Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy (NCT01002950) | Kubota Vision Inc. | 2009-10-01 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy (NCT00973011) | Genentech, Inc. | 2009-09-01 |
| Geographic Atrophy Treatment Evaluation (NCT00890097) | Alcon Research | 2009-04-01 |
| The Natural History of Geographic Atrophy Progression (GAP) Study (NCT00599846) | Alcon Research | 2007-12-01 |
| Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration (NCT00429936) | Sirion Therapeutics, Inc. | 2006-12-01 |
| OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration (NCT00306488) | National Institutes of Health Clinical Center (CC) | 2006-03-01 |
| A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population (NCT01666821) | Shanghai University of Traditional Chinese Medicine | 2004-05-01 |